Plasma glucagon levels (Figure 4D) were markedly higher in T2D-PRL-2903-treated animals, within an hour of dosing (which was at t = 0 min), as compared to T2D vehicle controls (100.9 ± 50.6 pg/mL vs. 12.8 ± 9.9 pg/mL, p < 0.0001) and glucagon values remained higher throughout the duration of the hypoglycemic challenge. The gene discussed is GCG; the disease is type 2 diabetes mellitus.